IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	: 10/517,518
Applicant	: Stefan SPERL
Filed	: July 1, 2005 (371 filing date)
TC/A.U.	: 1614
Examiner	: Not yet assigned.
Docket No.	: 2923-671
Customer No.	: 6449
Confirmation No.	: 1246

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

On July 1, 2005, Applicant filed this application with an Information Disclosure Statement submitting the International Search Report in the corresponding international application. We now enclose copies of the references that have been received from Applicant along with a copy of the previously filed PTO-1449 for the Examiner's convenience. Counsel does not have English translations of the foreign patent documents. English language abstracts are included with printed publications WO 02/074756, WO 0004954 and WO/0170204. An English language abstract of DE19940389 and DE10029014 is also enclosed.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By _____
Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/jvtrhl
Enclosures
L:\2923\671\2923.671.supp.IDS.wpd

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	
Application Number	10/517,518
Filing Date	December 3, 2004
First Named Inventor	Stefan SPERL
Group Art Unit	
Examiner Name	
Confirmation No.	
Attorney Docket Number	2923-671

Sheet	1	of	2

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3] Code	Number[4]	Kind[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
	1.	WO	02/074756	A	Pentapham AG	9/26/02	
	2.	WO	00/04954	A	Stuerzebecher et al	2/3/00	
	3.	DE	199 40 389	A	Wilex Biotechnology GmbH	3/1/01	
	4.	DE	100 29 014	A	Univ Schiller Jena	12/20/01	
	5.	WO	01/070204	A3	Max Planck	9/27/01	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code. [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	
Application Number	10/517,518
Filing Date	December 3, 2004
First Named Inventor	Stefan SPERL
Group Art Unit	
Examiner Name	
Confirmation No.	
Attorney Docket Number	2923-671

Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	6.	Sturzebecher et al., "3-Amidinophenylalanine-based inhibitors of Urokinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 21, November 1, 1999, pgs. 3147-3152.	
	7.	Magdolen et al., "Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator", "ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 477, 2000, pgs. 331-341.	
	8.	Heechung et al., "Selective Inhibition of Urokinase by Substituted Phenylguanidines:...", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 33, no. 11, 1990, pgs. 2956-2961.	
	9.	Sperl et al., "(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 10, 9 May 2000, pgs. 5113-5118.	
	10.	Nienaber et al., "Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, 10 March 2000, pgs. 7239-7248.	

Examiner Signature		Date Considered	